Document Detail


Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
MedLine Citation:
PMID:  11920464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The objective of the current study was to assess rigorously whether serum prostate specific antigen (PSA) determination can eliminate the need for bone scans in Japanese patients with newly diagnosed prostate carcinoma with serum PSA levels < or = 10 ng/mL. METHODS: A retrospective assessment of 1294 patients with newly diagnosed, untreated prostate carcinoma was conducted at the authors' institutions. All patients underwent a bone scan, serum PSA measurement, and core needle biopsy of the prostate. The receiver operating characteristic curve for identifying a positive bone scan based on serum PSA levels and a decision tree were analyzed to determine the expected 10-year cumulative cost and disease specific survival rate. Two competing strategies were used: PSA alone and PSA plus baseline bone scan. For the PSA-alone strategy, a baseline bone scan was performed only when the patient had a serum PSA level > 10 ng/mL. RESULTS: The proportion of positive bone scans in patients with serum PSA levels < or = 10.0 ng/mL was 1.33%. The area under the receiver operating characteristic curve was 0.870. Patients with a Gleason Grade > or = 3 tumors or with a Gleason score > or = 7 had a higher proportion of positive bone scans. The 10-year disease specific survival rates with the PSA-alone strategy and the PSA-plus-bone-scan strategy were the same. The PSA-alone strategy was minimally cost effective, with a savings of $16.00 (U.S.) in the cumulative net cost per patient over the PSA-plus-bone-scan strategy. CONCLUSIONS: The current results suggest that baseline bone scans can be eliminated in patients with newly diagnosed prostate carcinoma in Japan who have serum PSA levels < or = 10 ng/mL. Apparently, it is possible to omit baseline bone scans for patients with a Gleason Grade < or = 2 tumors or with a Gleason score < or =6.
Authors:
Shigeru Kosuda; Ichiro Yoshimura; Taku Aizawa; Kiyoshi Koizumi; Koichiro Akakura; Junpei Kuyama; Kiyoshi Ichihara; Junji Yonese; Mitsuru Koizumi; Jun Nakashima; Hirofumi Fujii
Related Documents :
3339664 - Creatine phosphokinase-mb assays in patients with suspected myocardial contusion: diagn...
475524 - Inferior vena cava obstruction. a complication of prostate cancer.
8909304 - Phase i/ii trial of combined 131i anti-cea monoclonal antibody and hyperthermia in pati...
19272664 - Intra-operative pubic arch interference during prostate seed brachytherapy in patients ...
20383864 - Pattern of urinary sediments and comparison with dipstick urinalysis in hypertensive ni...
22574854 - Diagnosis and inflammatory response of patients with candiduria.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  94     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-28     Completed Date:  2002-04-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  964-72     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10340
Affiliation:
Department of Radiology, National Defense Medical College, Namiki, Tokorozawa, Japan. nucleark@ndmc.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Biopsy, Needle
Bone Neoplasms / diagnosis,  radionuclide imaging,  secondary*
Carcinoma / pathology*
Decision Making
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / pathology*
Retrospective Studies
Sensitivity and Specificity
Survival Analysis
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.
Next Document:  Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal ...